Causal Vaccine Effects on Post-infection Outcomes in the Naturally Infected

Allison Codi, Elizabeth Rogawski McQuade, Razieh Nabi, Mats Stensrud, Kaeum Choi, David Benkeser · 2026

Read Causal Vaccine Effects on Post-infection Outcomes in the Naturally Infected by Allison Codi, Elizabeth Rogawski McQuade, Razieh Nabi, Mats Stensrud, Kaeum Choi, David Benkeser (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2604-00133.txt.

Introduction

Codi and five colleagues study what vaccines do after infection, for the naturally infected, people who would catch the disease even without a shot. Usual methods look only at the doomed stratum, those infected with or without vaccination, which understates benefit by leaving out cases the shot prevents. The authors set bounds under weak rules and pin down single values under an exclusion rule or partial principal ignorability. A rotavirus trial reanalysis then shows a shielding effect on antibiotic use on those grounds, where cruder group analyses show little.

Catalog record

CREATORAllison Codi, Elizabeth Rogawski McQuade, Razieh Nabi, Mats Stensrud, Kaeum Choi, David Benkeser
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE143252
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2604.00133

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Causal Vaccine Effects on Post-infection Outcomes in the Naturally Infected Allison Codi, Elizabeth Rogawski McQuade, Razieh Nabi, Mats Stensrud, Kaeum Choi, David Benkeser Abstract Understanding vaccine effects on post-infection outcomes is critical for evaluating the full value proposition of a vaccine. However, defining appropriate causal effects on such outcomes is challenging because infection is affected by vaccination. Existing principal stratification approaches focus on the Doomed stratum, individuals who would be infected regardless of vaccine receipt. For many relevant outcomes, however, this estimand will understate vaccine benefit by excluding individuals whose adverse post-infection outcomes are improved because vaccination prevented infection. We therefore propose causal estimands for post-infection outcomes in the Naturally Infected , individuals who would be infected in absence of vaccine. We derive bounds under minimal assumptions and give point identification results under an exclusion restriction and/or a partial principal ignorability assumption. For point-identified settings, we develop efficient one-step estimators with robustness properties under inconsistent nuisance parameter estimation. We further show under what conditions the same identification functional can be interpreted as targeting an effect among individuals exposed to a sufficiently infectious dose of the pathogen, thereby avoiding direct reliance on cross-world parameters and fundamentally untestable causal assumptions. Simulations show that the bounds are valid but often wide, and that the point estimators perform well when their identifying assumptions hold. In a reanalysis of a rotavirus vaccine trial, marginal and Doomed-stratum analyses showed little evidence of an effect on antibiotic use, whereas analyses targeting the Naturally Infected suggested a protective effect under principal ignorability-based assumptions. 1 Introduction Vaccines primarily reduce the burden of infectious diseases by preventing infections entirely and/or lessening the severity of disease following an infection. Vaccines can further prevent or improve sequelae of infections and reduce the likelihood of onward transmission of a pathogen in infected individuals. To help establish the full value proposition of a vaccine, it is important to appropriately quantify vaccine effects on each of these outcomes. In this work, we refer to the primary endpoint of interest as an infection , with the understanding that in some settings the primary endpoint is clinical disease caused by an infection. While effects on infection are straightforward to characterize, for endpoints that occur after infection, quantifying vaccine effects can be more challenging. A comparison of post-infection outcomes between infected vaccinated and infected unvaccinated individuals will not generally represent an appropriate causal effect of vaccines due to selection bias: individuals who become infected after receiving a vaccine may differ from those who become infected in absence of the vaccine. A common solution in the literature has been to consider vaccine effects in the principal stratum of individuals who would be infected irrespective of whether they received vaccine, referred to as the Doomed principal stratum ( 19 ) . Such analyses often report estimates of the bounds on vaccine effects in this stratum, with estimation based on maximum likelihood or Bayesian estimators ( 19 ; 44 ) and have been employed both in primary and secondary evaluation of vaccines. 29 compared various statistical tests for primary endpoints of clinical trials that combine infection and post-infection endpoints, where the post-infection endpoints are evaluated in the Doomed principal stratum. Similar methods were used to evaluate varicella vaccines to prevent and reduce the severity of herpes zoster infections ( 31 ) . Here, we argue that for many relevant post-infection endpoints, a comparison of outcomes in the Doomed principal stratum likely understates the vaccine’s true benefit. By construction, this comparison excludes individuals whose post-infection outcomes were improved because the vaccine successfully prevented a primary infection. These individuals are precisely those who we expect to benefit most with respect to post-infection outcomes. As a result, the estimand omits an important component of the vaccine’s effect, leading to an underestimation of its positive impact. Alternatively, a comparison of the average post-infection outcome between all vaccinated and unvaccinated individuals is also unlikely to well characterize vaccine benefit. The population-level difference in outcomes is often small, as only a limited proportion of participants are likely to experience an infection during the study period even without vaccine. Assuming only participants who would have been infected without vaccine are likely to benefit from a vaccine effect on their post-infection outcomes, the vast majority of the trial participants who remain uninfected (i.e., are Immune) consequently show little or no difference in their post-infection outcome. This dilution effect by the Immune, where the benefit among the relatively few is overshadowed by the lack of significant impact in the majority uninfected population, reduces the statistical power to detect a meaningful improvement in post-infection outcomes attributable to the vaccine. We propose instead a different estimand for quantifying vaccine effects on post-infection endpoints: the effect of vaccine in the principal strata who would be infected in the absence of vaccine, a group of individuals that we term the Naturally Infected . This group includes the Doomed stratum in addition to the Protected stratum, individuals for whom the vaccine prevents infection. We discuss various assumptions that can be used to identify these effects and sensitivity analyses to these assumptions. Finally, we discuss a different estimand in the context of infectious diseases, that overcomes concerns that have been raised about the unobservable nature of such estimands in the literature ( 37 ) . This allows us to overcome the reliance of principal stratum estimands on fundamentally untestable assumptions via the introduction of a necessary and sufficient exposure to a pathogen and show that principal strata effects often align with effects in the subgroup of individuals who naturally encounter such exposure events. 2 Background We consider the setting of a randomized controlled vaccine trial where the observed data consist of X , a vector of information measured on trial participants at the time of enrollment, Z , a binary indicator of vaccine assignment (=1 if vaccine; =0 if placebo or control vaccine), S , a binary indicator of experiencing an infection or clinical disease caused by the pathogen of interest during the trial, and Y , a post-infection outcome measured at a fixed time following infection or at the end of the study follow-up period. We denote the vector of observed data by O=(X,Z,S,Y) and assume that O\sim P for a probability distribution P . We assume P falls in a model that is nonparametric up to positivity assumptions described later. We also consider counterfactual outcomes for the n independent trial participants. Let \bm{Z}=(Z_{1},\dots,Z_{n}) and \bm{S}=(S_{1},\dots,S_{n}) denote the vaccine assignment vector and the infection status vector for all individuals in the trial, respectively. For each individual i , we let S_{i}(\bm{z}) denote the infection outcome that would be observed under an intervention that sets \bm{Z}=\bm{z} . Similarly, we let Y_{i}(\bm{z},\bm{s}) denote the post-infection outcome for the i -th individual under an intervention that sets \bm{Z}=\bm{z} and \bm{S}=\bm{s} . To simplify our exposition, we assume no interference and causal consistency (see Assumptions 1-2 in Supplement A), which allows us to write potential outcomes as S(z) , Y(z) , and Y(z,s) . These assumptions are likely reasonable in Phase 3 studies, where participants represent a relatively small fraction of the at-risk population and the vaccine studied in the trial is not available to individuals outside of the

Read the complete text